Scenarios that move VKTX
Viking Therapeutics, Inc. - Common Stock
Scenarios that move VKTX: 12 analyses, 4 positive, 8 negative.
- · Syndax stock falls 16% as Phase II fibrosis study misses primary goal — ▼ · impact -40 · confidence low · horizon quarters
- · Viking Therapeutics advances oral obesity drug to Phase III — ▲ · impact +93 · confidence high · horizon immediate
- · Spyre Therapeutics prices $350 million public stock offering — ▼ · impact -25 · confidence low · horizon immediate
- · Zealand Pharma reports positive survodutide Phase III weight loss results — ▼ · impact -46 · confidence medium · horizon immediate
- · Novo Nordisk's Ozempic outperforms Lilly's Mounjaro on cardiovascular risk — ▼ · impact -50 · confidence medium · horizon weeks
- · Lilly reports strong weight loss results for new drug — ▼ · impact -70 · confidence medium · horizon immediate
- · Novo and Hengrui sign exclusive license for oral GLP-1/GIP drug — ▼ · impact -52 · confidence medium · horizon immediate
- · Pharma stock soars 150% after injectables deal with Novo — ▼ · impact -31 · confidence medium · horizon weeks
- · ◇ What if… Oral GLP-1 drugs replace injectable treatments — ▲ · impact +78 · confidence high · horizon quarters
- · Oruka Therapeutics reports positive week 28 ORKA-001 trial data — ▲ · impact +50 · confidence low · horizon weeks
- · Viking Therapeutics stock skyrockets in Tuesday trading — ▲ · impact +96 · confidence medium · horizon immediate
- · Eli Lilly Weight Loss Pill Shows Better Results Than Injectable Competitors In Phase 3 Trial — ▼ · confidence medium